Intellect Neurosciences Obtains Patent Allowance From the United States Patent and Trademark Office in Relation to Its TOC-1 ...
November 14 2013 - 2:15PM
Intellect Neurosciences, Inc. (OTCBB:ILNS), a biopharmaceutical
company engaged in the discovery and development of
disease-modifying therapeutic and diagnostic agents for the
treatment of Alzheimer's and other neurological diseases, today
announced it obtained a Notice of Allowance from the United States
Patent and Trademark Office (USPTO). The patent allowance is in
relation to TOC-1, a monoclonal antibody that selectively binds
neurotoxic pre-fibrillar tau aggregates which are important
pathological components in Alzheimer's disease (AD) and other
neurodegenerative tauopathies. Intellect previously obtained
development and commercialization rights to TOC-1 under an
exclusive license agreement with Northwestern University.
New findings regarding the antibody were recently published in
the Journal of Alzheimer's Disease in a paper titled, "TOC1:
Characterization of a Selective Oligomeric Tau Antibody" written by
Lester Binder, Ph.D., the Abbott Laboratories, Duane and Susan
Burnham Research Professor of Genetic and Molecular Medicine, at
Northwestern University. These data underscore its potential as a
powerful biochemical tool that can be used to better investigate
the involvement of tau in neurodegenerative diseases.
"The new patent allowance from the USPTO awarded to Intellect
Neurosciences is of particular significance in view of the
considerable attention being given to the important role of
pre-fibrillar aggregated forms of tau in the pathogenesis of AD and
other tauopathies such as cortico-basal ganglia degeneration and
progressive supranuclear palsy," said Professor Moses V. Chao,
Molecular Neurobiology Program Skirball Institute of Biomolecular
Medicine NYU School of Medicine. "TOC-1 reacts with brain
pathology in each of these types of diseases and is undoubtedly an
important biochemical tool that will be extremely helpful to
academic and industry researchers".
The Company is exploring ways to commercialize TOC-1, initially
as an essential tool which is required for research, but also for
further development clinically.
About Intellect Neurosciences
Intellect Neurosciences, Inc. develops innovative approaches
aimed at arresting or preventing Alzheimer's disease and other
neurodegenerative diseases, with a specific focus on
proteinopathies. Intellect's pipeline includes therapeutic
vaccines, antibodies and neuroprotective antibody drug conjugates.
For more information, please visit www.intellectns.com.
Safe Harbor Statements Regarding Forward Looking
Statements
The statements in this release and oral statements made by
representatives of Intellect Neurosciences relating to matters that
are not historical facts (including, without limitation, those
regarding future performance or financial results, the timing or
potential outcomes of research collaborations or clinical trials,
any market that might develop for any of Intellect's product
candidates and the sufficiency of Intellect's cash and other
capital resources) are forward-looking statements that involve
risks and uncertainties, including, but not limited to, the
likelihood that actual performance or results could materially
differ, that future research will prove successful, the likelihood
that any product in the research pipeline will receive regulatory
approval in the United States or abroad, or Intellect's ability to
fund such efforts with or without partners. Intellect undertakes no
obligation to update any of these statements. Readers are cautioned
not to place undue reliance on these forward-looking statements,
which speak only as to the date hereof. Accordingly, any
forward-looking statements should be read in conjunction with the
additional risks and uncertainties detailed in Intellect's filings
with the Securities and Exchange Commission, including those
discussed in Intellect's Annual Report on Form 10-K (file no.
333-128226), filed on October 15, 2013.
CONTACT: ir@intellectns.com